Overview

Combination Chemotherapy and Peripheral Stem Cell Transplant in Treating Patients With Relapsed Hodgkin's Lymphoma

Status:
Unknown status

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplant may allow the doctors to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which combination chemotherapy regimen given before peripheral stem cell transplant is more effective in treating relapsed Hodgkin's lymphoma. PURPOSE: This randomized phase III trial is comparing different regimens of combination chemotherapy followed by peripheral stem cell transplant to see how well they work in treating patients with relapsed Hodgkin's lymphoma.

Phase:

Phase 3

Details

Lead Sponsor:

German Hodgkin's Lymphoma Study Group

Collaborators:

EBMT Solid Tumors Working Party
European Organisation for Research and Treatment of Cancer - EORTC

Treatments:

Carmustine
Cyclophosphamide
Cytarabine
Dexamethasone
Etoposide
Melphalan
Methotrexate
Vincristine